Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Parkinson's disease | R-HSA-1643685 | 0 | N-acetyl-L-leucine | 70912 | drug-path |
| Cardiac muscle contraction | R-HSA-397014 | map04260 | N-acetyl-L-leucine | 70912 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | N-acetyl-L-leucine | 70912 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | tonzonium bromide | 9433 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | tonzonium bromide | 9433 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | tonzonium bromide | 9433 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | tonzonium bromide | 9433 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | tonzonium bromide | 9433 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | tonzonium bromide | 9433 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | tonzonium bromide | 9433 | drug-path |
| Chemokine signaling pathway | R-HSA-168638 | map04062 | tonzonium bromide | 9433 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | tonzonium bromide | 9433 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | tonzonium bromide | 9433 | drug-path |
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | tonzonium bromide | 9433 | drug-path |
| Wnt signaling pathway | R-HSA-195721 | map04310 | tyloxapol | 5281416 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | tyloxapol | 5281416 | drug-path |
| Focal adhesion | R-HSA-354113 | map04510 | tyloxapol | 5281416 | drug-path |
| ECM-receptor interaction | R-HSA-373711 | map04512 | tyloxapol | 5281416 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | tyloxapol | 5281416 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | tyloxapol | 5281416 | drug-path |